与阿伐可泮治疗相关的药物性肝损伤
本研究纳入2021年9月至2024年3月日本多中心接受阿伐可泮治疗的22例ANCA相关性血管炎患者,用RECAM-J 2023评估药物性肝损伤。9例(40.9%)发生药物性肝损伤,其中4例(44.4%)出现总胆红素升高的严重肝损伤,1例发展为胆管消失综合征并死亡。
要点
- 22例接受阿伐可泮治疗的ANCA相关性血管炎患者中9例(40.9%)发生药物性肝损伤。
- 9例药物性肝损伤中4例(44.4%)为伴总胆红素升高的严重肝损伤。
- 1例发生胆管消失综合征并死亡。
核心结论
- 阿伐可泮诱导的药物性肝损伤在日本相对常见且可能致命。
- 作者建议考虑频繁的实验室随访,尤其针对老年和低体重患者。
研究设计与样本
- 本研究纳入2021年9月至2024年3月在日本多个中心接受阿伐可泮治疗的22例ANCA相关性血管炎患者。
- 药物性肝损伤采用日本版修订版电子因果评估方法(RECAM-J 2023)评估。
主要发现
- 22例接受阿伐可泮治疗的患者中9例(40.9%)发生药物性肝损伤,其中显微镜下多血管炎6例、肉芽肿性多血管炎3例。
- 9例药物性肝损伤中4例(44.4%)在开始阿伐可泮治疗后数周出现伴总胆红素升高的严重肝损伤。
- 9例药物性肝损伤中8例(88.9%)在停用阿伐可泮及其他药物后好转,1例发生胆管消失综合征并死亡。
- 阿伐可泮诱导的药物性肝损伤分为三种模式:1型为无总胆红素升高的短期损伤;2型为伴总胆红素升高的短暂胆汁淤积性肝损伤;3型为伴显著总胆红素升高的失代偿性肝损伤(胆管消失综合征)。
- 日本患者中伴总胆红素升高的严重药物性肝损伤的危险因素包括年龄较大、体重指数较低及开始阿伐可泮治疗后早期发生药物性肝损伤。
临床怎么用
- 作者建议考虑频繁的实验室随访,尤其针对老年和低体重患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The efficacy of avacopan as remission induction therapy for Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (AAV) is well-established. However, concerns regarding liver injury post-avacopan treatment remain, especially in Japan. Therefore, this study aimed to investigate drug-induced liver injury (DILI) associated with avacopan treatment. METHODS: This study included 22 patients with AAV who were treated with avacopan at multiple centres in Japan between September 2021 and March 2024. DILI was assessed by the Japanese version of a revised electronic causality assessment method (RECAM-J 2023). RESULTS: Among the 22 patients treated with avacopan, DILI was observed in nine cases (40.9%): six with microscopic polyangiitis and three with granulomatosis with polyangiitis. Severe DILI with elevated total bilirubin (T-Bil) was observed in four of the nine patients (44.4%), a few weeks after the initiation of avacopan therapy. Eight of the nine patients (88.9%) with DILI improved after discontinuation of avacopan and other medications, and one patient developed vanishing bile duct syndrome (VBDS) leading to death. Avacopan-induced DILI was classified into three patterns: 1, short-term injury without T-Bil elevation; 2, transient cholestatic liver injury with T-Bil elevation; 3, decompensated liver injury with marked T-Bil elevation (VBDS). The risk factors for severe DILI with T-Bil elevation in Japanese patients included older age, lower body mass index and early onset DILI following the initiation of avacopan treatment. CONCLUSION: Avacopan-induced DILI is relatively common in Japan and could be lethal. Frequent laboratory follow-ups should be considered, especially for elderly and low-body-weight patients.
引用
- Mori K, Shirai T, Mutoh T, et al. Drug-induced liver injury related to avacopan therapy. Rheumatology (Oxford). 2025. PMID: 39672792. doi:10.1093/rheumatology/keae689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。